MENU
FEB 24, 2021 12:00 PM PST

Deep Mechanistic profiling of immune oncology drug combinations in cancer patients with CIVO intratumoral micro-dosing and NanoString's GeoMx® Digital Spatial Profiler

Sponsored by: NanoString Technologies
C.E. Credits: P.A.C.E. CE Florida CE
Speakers
  • Director of Scientific Operations, Presage Biosciences
    Biography

      Jason Frazier is the Director of Scientific Operations for Presage Biosciences, a Phase 0 clinical research organization.  He oversees Presage’s testing lab and preclinical research lab operations in support of partner sponsored clinical and preclinical research.  He has spent the past ten years at Presage working to develop and expand the novel CIVO micro-dosing platform as well as implementing new assay technologies to assess biological responses in CIVO micro-dosed patient tumor studies.  Prior to joining Presage, he worked as a scientist at Targeted Growth and at Rosetta Inpharmatics/Merck Research Laboratories working on development of a lentiviral shRNA High Throughput Screening platform for Merck biomarker and target discovery efforts.

    • Sr Director of Translational Science, NanoString Technologies
      Biography

        Sarah Warren is the Senior Director of Translational Science at NanoString Technologies where she leverages multiplexed, molecular profiling technologies to address key research areas in oncology, immunology, and beyond. Her role enables her to work with academics, biopharmas, and clinicians to identify unmet needs in translational research and create novel products for transcriptional and proteomic profiling. She is also active in the immuno-oncology research community to promote the science and application of cancer immunotherapy to improve patient outcomes. Prior to joining NanoString, she was a founder and director of research at Oncofactor Corp., a Seattle biotech startup focused on developing therapeutics which targeted novel immune checkpoints. She has a PhD in immunology from the University of Washington and performed her graduate work at the Institute for Systems Biology.


      Abstract

      With an introduction by Sarah Warren, the Senior Director of Translational Science, this webinar will open by providing a brief technology overview of NanoString Technologies. Dr. Warren will give an overview of the NanoString digital spatial profiling platform, GeoMx® DSP, along with curated gene expression panels that focus on all aspects of the biomarker and drug development continuums. Following the introduction will be speaker Jason Frazier from Presage Biosciences. Despite over four thousand clinical trials designed to investigate combinations of various anti-cancer agents with PD1/PD-L1 targeting checkpoint inhibitors (CPI), few have demonstrated significant clinical improvement over CPI alone.  This suggests the need for far greater mechanistic understanding of tumor cell and microenvironment response to drug exposure to guide development of complex (≥ 3 drug) combination treatments.  Here, we show how an approach based on two technologies, the Presage Comparative In Vivo Oncology (CIVO) Platform and the Nanostring GeoMx Digital Spatial Profiler (GeoMx DSP), can provide information on the activity of drugs in vivo at the cellular level, delineate the cellular targets and mechanisms of action, and provide a path to rapid identification of effective drug combinations, all in the most authentic and relevant context, the human cancer patient. The CIVO platform enables trackable multiplexed intratumoral delivery of spatially restricted micro-dosed drugs, either as single agents or in combinations, allowing simultaneous evaluation of the localized tumor response to multiple different drugs and drug combinations in the native tumor microenvironment (TME).  By combining GeoMx digital spatial profiling with multiplex CIVO micro-dosing in human sarcomas, we evaluated over 1800 gene transcripts per site of drug exposure and measured drug-, cell-, and region-specific transcriptional responses in individual patient tumors.  We showed T-cell specific activation following exposure to localized combination of aldesleukin (recombinant IL-2) and nivolumab (anti-PD1).  Importantly, we show how such events indicating T-cell activation may be dampened by feedback loops involving immune suppressive responses such as elevation of IDO-1 in the non T-cell compartment of the TME. Ultimately, the capability to perform high-plex spatial analysis across multiplex micro-dosed patient tumors will allow us to better understand the mechanism of action of drugs and responses in different compartments of the TME and evaluate the inter-individual variation in the responses to many different IO drugs and drug candidates.

      Learning Objectives:

      1. Understand some key bulk gene expression tools available for oncology biomarker and drug development research

      2. Understand the concept of spatially resolved transcriptomics- Nature’s 2020 Method of the Year

      3. Understand how two synergistic platforms were used to profile IO drug combinations in a real world setting at a biotech company


      Show Resources
      You May Also Like
      OCT 29, 2020 6:00 AM PDT
      C.E. CREDITS
      OCT 29, 2020 6:00 AM PDT
      Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
      NOV 16, 2020 8:00 AM PST
      C.E. CREDITS
      NOV 16, 2020 8:00 AM PST
      Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
      NOV 18, 2020 8:00 AM PST
      C.E. CREDITS
      NOV 18, 2020 8:00 AM PST
      DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
      SEP 10, 2020 9:00 AM PDT
      C.E. CREDITS
      SEP 10, 2020 9:00 AM PDT
      Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
      APR 01, 2021 8:00 AM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      APR 01, 2021 8:00 AM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
      SEP 02, 2020 7:00 AM PDT
      C.E. CREDITS
      SEP 02, 2020 7:00 AM PDT
      DATE: September 2, 2020 TIME: 03:00pm PDT, 6:00pm EDT Spatial omics is an expanding collection of methods to examine biological molecules in their geographical context. By retaining the prec...
      Loading Comments...
      Show Resources
      Attendees
      • See more